China SXT Pharmaceuticals (SXTC) Receivables - Other (2018 - 2026)
China SXT Pharmaceuticals (SXTC) posted quarterly Receivables - Other of $15.8 million for Q1 2026, up 3694.78% year-over-year from $417563.0 in Q1 2025, and up 1061.33% quarter-over-quarter from $1.4 million in Q3 2025.
China SXT Pharmaceuticals (SXTC) Receivables - Other (2018 - 2026) Analysis & Trends
China SXT Pharmaceuticals' Receivables - Other history runs 9 years deep, the most recent figure standing at $15.8 million for Q1 2026.
- In Q1 2026, Receivables - Other rose 3694.78% year-over-year to $15.8 million; the TTM figure through Mar 2026 stood at $15.8 million (up 3694.78% YoY), while the FY2026 annual figure was $15.8 million, up 3694.78% from the prior year.
- Receivables - Other for Q1 2026 stood at $15.8 million, up from $1.4 million in the prior quarter.
- The five-year high for Receivables - Other was $15.8 million in Q1 2026, with the low at $83634.0 in Q1 2024.
- The 5-year median for Receivables - Other is $839314.0 (2022), against an average of $2.8 million.
- The sharpest annual moves came in 2024 and 2026: Receivables - Other sank 63.74% in 2024, then jumped 3694.78% in 2026.
- China SXT Pharmaceuticals' Receivables - Other stood at $2.7 million in 2022, then slumped by 91.61% to $230642.0 in 2023, then jumped by 378.17% to $1.1 million in 2024, then climbed by 23.72% to $1.4 million in 2025, then jumped by 1061.33% to $15.8 million in 2026.
- Business Quant data shows SXTC's Receivables - Other at $15.8 million in Q1 2026, $1.4 million in Q3 2025, and $417563.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | China SXT Pharmaceuticals | 31,562.64 | -28.14 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.85 Mn |
| Mar 31, 2026 | 15.85 Mn |
| Sep 30, 2025 | 1.36 Mn |
| Sep 30, 2025 | 1.36 Mn |
| Mar 31, 2025 | 417,563.00 |
| Mar 31, 2025 | 417,563.00 |
| Sep 30, 2024 | 1.10 Mn |
| Sep 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 83,634.00 |
| Mar 31, 2024 | 83,634.00 |
| Mar 31, 2023 | 230,642.00 |
| Mar 31, 2023 | 230,642.00 |
| Sep 30, 2022 | 2.75 Mn |
| Sep 30, 2022 | 2.75 Mn |
| Mar 31, 2022 | 575,773.00 |
| Mar 31, 2022 | 575,773.00 |
| Sep 30, 2021 | -3.89 Mn |
| Sep 30, 2021 | -3.89 Mn |
| Mar 31, 2021 | 180,370.00 |
| Mar 31, 2021 | 180,370.00 |